Matricelf Ltd Cash Flow Conversion Efficiency
Matricelf Ltd cash flow conversion efficiency. Based on the latest financial reports, Matricelf Ltd (MTLF) has a cash flow conversion efficiency ratio of -997.589x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-8.28 Million ≈ $-22.18K USD) by net assets (ILA8.29K ≈ $22.24 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Matricelf Ltd (2019–2024)
Cash flow conversion efficiency of Matricelf Ltd from 2019 to 2024. This chart illustrates how Matricelf Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Matricelf Ltd for real-time trading data and today's change.
Matricelf Ltd Cash Flow Conversion Ratio Explained
Matricelf Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Matricelf Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Matricelf Ltd ranked by their cash flow conversion efficiency. Also see Matricelf Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SCI Electric Public Company Limited
BK:SCI
|
0.031x |
|
Coats Group PLC
LSE:COA
|
0.184x |
|
Jacques Bogart SA
PA:JBOG
|
0.688x |
|
Music Broadcast Limited
NSE:RADIOCITY
|
0.017x |
|
Black Hawk Acquisition Corporation
NASDAQ:BKHA
|
-0.012x |
|
Genius Group Ltd
NYSE MKT:GNS
|
-0.103x |
|
Alumil Rom Industry SA
RO:ALU
|
0.117x |
|
Mene Inc
V:MENE
|
0.048x |
Annual Cash Flow Conversion Efficiency for Matricelf Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Matricelf Ltd from 2019 to 2024. Review MTLF free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA15.17 Million ≈ $40.66K |
ILA-11.75K ≈ $-31.51 |
-0.001x | -98.09% |
| 2023-12-31 | ILA26.80 Million ≈ $71.86K |
ILA-10.49K ≈ $-28.12 |
0.000x | +99.83% |
| 2022-12-31 | ILA35.79 Million ≈ $95.96K |
ILA-8.30 Million ≈ $-22.25K |
-0.232x | +8.20% |
| 2021-12-31 | ILA26.23 Million ≈ $70.32K |
ILA-6.62 Million ≈ $-17.76K |
-0.253x | +79.57% |
| 2020-12-31 | ILA2.80 Million ≈ $7.50K |
ILA-3.46 Million ≈ $-9.27K |
-1.236x | -1354.61% |
| 2019-12-31 | ILA3.62 Million ≈ $9.71K |
ILA-307.80K ≈ $-825.19 |
-0.085x | -- |
About Matricelf Ltd
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company's regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, as well as for 3D bioprinting. Matricelf Ltd was incorporated in 20… Read more